KRN5500 in Treating Patients With Solid Tumors
A Phase I Trial of KRN5500 (NSC 650426) Given as a 72 Hour Continuous IV Infusion Every 21 Days in Patients With Solid Tumors
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
PRIMARY OBJECTIVES:
I. To establish the MTD and identify the DLTs of the investigational agent KRN5500 when administered by a 72-hr continuous i.v. infusion to patients with solid tumors who have failed standard therapy or for whom no standard therapy exists.
II. To establish and assess the safety of an appropriate dose for phase II studies.
III. To characterize the pharmacokinetics of KRN5500 in patients when administered by a 72 hr continuous IV infusion.
IV. To characterize the response to KRN5500 by FLT-PET scanning at the MTD.
SECONDARY OBJECTIVES:
I. To describe any preliminary evidence of antitumor activity. II. Establish pharmacodynamic relationships for the pharmacological effect of the drug upon surrogate markers of activity and host toxicity.
III. To compare the toxicity profiles for the 1 hr i.v. infusion and 72 hr continuous i.v. infusion administration schedules.
OUTLINE: This is a dose-escalation, multicenter study.
Patients receive KRN5500 IV over 24-72 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 1-3 patients receive KRN5500 at the starting dose over escalating infusion durations. After the longest duration of infusion time is safely reached, cohorts of 3-6 patients receive escalating doses of KRN5500 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are accrued to receive treatment with KRN5500 at the recommended phase II dose.
Patients are followed every 4 weeks until resolution of all toxicity.
PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study within 9-12 months.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02115
- Dana-Farber Cancer Institute
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Metastatic or inoperable malignancy, other than leukemia or a primary CNS tumor, for which there is no known curative or survival prolonging palliative therapy, or all such therapies have failed
- Life expectancy >= 2 months
- ECOG performance status =< 2
- WBC >= 3,000/mm^3
- ANC >= 1,500/mm^3
- Platelets >= 100,000/mm^3
- SGOT ≤ 2.5-times the upper limit of normal (ULN)
- SGPT ≤ 2.5-times the ULN
- Total bilirubin ≤ 1.5 mg/dl
- Serum creatinine ≤ 1.5 mg/dl
- ECG showing no evidence of acute ischemia or serious conduction abnormality
- >= 2 weeks since major surgery
- >= 3 weeks since chemotherapy or radiation therapy, except for nitrosoureas and mitomycin-C, in which case the interval shall be 6 weeks
- Women of childbearing potential must not be pregnant or lactating; all women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L of β-HCG) within 72 hr prior to receiving the study medication; KRN5500 has antiproliferative effects which may be harmful to the developing fetus or nursing infant
- Fertile males and females must use adequate contraception
- Central venous catheter placed at least one day prior to treatment
- Signed informed consent
Exclusion Criteria:
- A serious uncontrolled medical disorder or active infection that would impair the ability of the patient to receive study treatment
- Uncontrolled or significant pulmonary or cardiovascular disease, including a recent (6 months or less) myocardial infarction, any significant degree of congestive heart failure with or without medical treatment, any history of clinically significant atrial or ventricular arrhythmias, any history of second or third degree heart block, or prolonged QTc interval (greater than 450 ms) on electrocardiogram
- Active brain metastases including evidence of cerebral edema by CT scan or MRI, or progression from prior imaging study, any requirement for steroids, or clinical symptoms related to brain metastases
- A psychiatric illness that precludes the ability to provide informed consent
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Treatment (KRN5500)
Patients receive KRN5500 IV over 24-72 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 1-3 patients receive KRN5500 at the starting dose over escalating infusion durations. After the longest duration of infusion time is safely reached, cohorts of 3-6 patients receive escalating doses of KRN5500 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are accrued to receive treatment with KRN5500 at the recommended phase II dose. |
Studi correlati
Altri nomi:
Given IV
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Maximally tolerated dose (MTD) and dose limiting toxicities (DLTs) of KRN5500, based on the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0
Lasso di tempo: Up to 21 days
|
Up to 21 days
|
|
|
Grade 2 or greater toxic effects, based on the NCI CTC v2.0
Lasso di tempo: Up to 1 month after last course of study treatment
|
Up to 1 month after last course of study treatment
|
|
|
Plasma concentration-time levels of KRN5500 as determined by reversed-phase high-performance liquid chromatography with electrospray ionization mass spectrometric detection
Lasso di tempo: Up to 21 days
|
Analyzed by noncompartmental methods and/or nonlinear least squares regression using WinNonlin (Scientific Consulting, Inc.).
|
Up to 21 days
|
|
Response to KRN5500 by fluorothymidine-positron emission tomography (FLT-PET) scanning at the MTD in patients with measurable disease
Lasso di tempo: Up to 5 years
|
Up to 5 years
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Attività antitumorale
Lasso di tempo: Fino a 5 anni
|
Fino a 5 anni
|
|
Pharmacodynamic relationships for the pharmacological effect of the drug upon surrogate markers of activity and host toxicity
Lasso di tempo: Up to 21 days
|
Up to 21 days
|
|
Comparison among the toxicity profiles between the 1 hr i.v. infusion and 72 hr continuous i.v. infusion administration schedules
Lasso di tempo: Up to 1 month after last course of study treatment
|
Up to 1 month after last course of study treatment
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Joseph Eder, Dana-Farber Cancer Institute
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- NCI-2012-03132
- U01CA062490 (Sovvenzione/contratto NIH degli Stati Uniti)
- 00-102
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .